Drug-Induced Liver Injury Associated with Statins

Russo, Mark W.; Scobey, Martin; Bonkovsky, Herbert L.

doi:10.1055/s-0029-1240010

Cited by 137 publications

(114 citation statements)

References 40 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…New drugs: the growing use of drugs such as statins and biologic agents, which have been related to DILI with autoimmune features, which has prompted an increase in the diagnosis of DIAILD [36][37][38][39][40][41][42] . The diagnosis DIAILD represents a challenge to the clinician as there are neither histological, nor clinical features that are pathognomonic of true AIH, and HLA haplotypes do not convincingly distinguish between either entity.…”

Section: Histologymentioning

confidence: 99%

Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease

Castiella

Zapata

Lucena

et al. 2014

WJH

114

113

View full text Add to dashboard Cite

The aetiology of autoimmune hepatitis (AIH) is uncertain but the disease can be triggered in susceptible patients by external factors such as viruses or drugs. AIH usually develops in individuals with a genetic background mainly consisting of some risk alleles of the major histocompatibility complex (HLA). Many drugs have been linked to AIH phenotypes, which sometimes persist after drug discontinuation, suggesting that they awaken latent autoimmunity. At least three clinical scenarios have been proposed that refers to druginduced autoimmune liver disease (DIAILD): AIH with drug-induced liver injury (DILI); drug induced-AIH (DI-AIH); and immune mediated DILI (IM-DILI). In addition, there are instances showing mixed features of DI-AIH and IM-DILI, as well as DILI cases with positive autoantibodies. Histologically distinguishing DILI from AIH remains a challenge. Even more challenging is the differentiation of AIH from DI-AIH mainly relying in histological features; however, a detailed standardised histologic evaluation of large cohorts of AIH and DI-AIH patients would probably render more subtle features that could be of help in the differential diagnosis between both entities. Growing information on the relationship of drugs and AIH is being available, being drugs like statins and biologic agents more frequently involved in cases of DIAILD. In addition, there is some evidence on the fact that patients diagnosed with DIAILD may have had a previous episode of hepatotoxicity. Further collaborative studies in DIAILD will strengthen the knowledge and understanding of this intriguing and complex disorder which might represent different phenotypes across the spectrum of disease

show abstract

Section: Histologymentioning

confidence: 99%

Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease

Castiella

Zapata

Lucena

et al. 2014

WJH

114

113

View full text Add to dashboard Cite

show abstract

“…However, numerous clinical cases have been published reporting the various ADR induced by statins [18,19]. These ADRs include liver damage, myopathy and rhabdomyolysis, myalgias and polyneuropathy [20].…”

Section: Discussionmentioning

confidence: 99%

A Report of Six Clinical Cases of Lowered Blood Cholesterol Profile Associated with Supplementation with Polypeptide K (Diabegard<sup>®</sup>), a Polypeptide Isolated from the Seeds of <i>Momordica charantia</i> Linn

Sirn¹,

Lok²,

Ahmad³

et al. 2014

Trop. J. Pharm Res

View full text Add to dashboard Cite

“…Despite their widespread use, acute liver failure and death have rarely been reported in patients with statin hepatotoxicity. Multiple retrospective studies, as well as one large prospective randomised controlled trial demonstrate that statins can safely be given to hyperlipidaemic patients with compensated chronic liver disease (49).…”

Section: Epidemiological Studies On Statinsmentioning

confidence: 99%

Hepatotoxicity associated with statins

Karahalıl

Hare

Koç

et al. 2017

Archives of Industrial Hygiene and Toxicology

View full text Add to dashboard Cite

Treatment with statins is known all over the world. They are generally considered safe at therapeutic doses. Nevertheless, clinical trials are not enough to assess their scarce adverse effects such as idiosyncratic drug induced liver injury (DILI). Due to some conditions, such as concomitant usage (drug-drug interaction using an identical metabolising enzyme) and genetic polymorphisms, there is an increasing concern about their safety. Hepatotoxicity and rhabdomyolysis have begun to appear in published studies. Most of investigations have focused on both these adverse effects and mechanisms of drug induced toxicity. The present review has attempted to compile almost all of the existing studies on the hepatotoxicity of statins but not rhabdomyolysis. The aim of our study is to provide an overview of the studies on the statin-associated hepatotoxicity and to discuss the published studies. The researchers are of the opinion that the research on this topic is incomplete but extremely necessary.

show abstract

Drug-Induced Liver Injury Associated with Statins

Cited by 137 publications

References 40 publications

Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease

Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease

A Report of Six Clinical Cases of Lowered Blood Cholesterol Profile Associated with Supplementation with Polypeptide K (Diabegard<sup>®</sup>), a Polypeptide Isolated from the Seeds of <i>Momordica charantia</i> Linn

Hepatotoxicity associated with statins

Contact Info

Product

Resources

About